Article

Increasing Incidence of Sterile‐Site Infections Due to Non–Multidrug‐Resistant, Oxacillin‐Resistant Staphylococcus aureus Among Hospitalized Patients •

Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, MO 63110, USA.
Infection Control and Hospital Epidemiology (Impact Factor: 4.18). 02/2007; 28(1):95-7. DOI: 10.1086/509856
Source: PubMed

ABSTRACT

The incidence of community-associated, healthcare-associated, and hospital-acquired sterile-site infections due to methicillin-resistant Staphylococcus aureus (MRSA) isolates and the susceptibility of the isolates to non- beta -lactam antibiotics were evaluated for 549 hospitalized patients during a 3-year period. The incidence of community-associated MRSA infection increased significantly. The annual percentage of MRSA isolates from cases of healthcare-associated and hospital-acquired infection that were susceptible to 3 or more non- beta -lactam antibiotics increased significantly.

Download full-text

Full-text

Available from: Garrett E Schramm, Jan 22, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Not Available
    No preview · Conference Paper · Aug 1963
  • [Show abstract] [Hide abstract]
    ABSTRACT: As the epidemiology of infections with methicillin-resistant Staphylococcus aureus (MRSA) changes, accurate information on the scope and magnitude of MRSA infections in the US population is needed. To describe the incidence and distribution of invasive MRSA disease in 9 US communities and to estimate the burden of invasive MRSA infections in the United States in 2005. Active, population-based surveillance for invasive MRSA in 9 sites participating in the Active Bacterial Core surveillance (ABCs)/Emerging Infections Program Network from July 2004 through December 2005. Reports of MRSA were investigated and classified as either health care-associated (either hospital-onset or community-onset) or community-associated (patients without established health care risk factors for MRSA). Incidence rates and estimated number of invasive MRSA infections and in-hospital deaths among patients with MRSA in the United States in 2005; interval estimates of incidence excluding 1 site that appeared to be an outlier with the highest incidence; molecular characterization of infecting strains. There were 8987 observed cases of invasive MRSA reported during the surveillance period. Most MRSA infections were health care-associated: 5250 (58.4%) were community-onset infections, 2389 (26.6%) were hospital-onset infections; 1234 (13.7%) were community-associated infections, and 114 (1.3%) could not be classified. In 2005, the standardized incidence rate of invasive MRSA was 31.8 per 100,000 (interval estimate, 24.4-35.2). Incidence rates were highest among persons 65 years and older (127.7 per 100,000; interval estimate, 92.6-156.9), blacks (66.5 per 100,000; interval estimate, 43.5-63.1), and males (37.5 per 100,000; interval estimate, 26.8-39.5). There were 1598 in-hospital deaths among patients with MRSA infection during the surveillance period. In 2005, the standardized mortality rate was 6.3 per 100,000 (interval estimate, 3.3-7.5). Molecular testing identified strains historically associated with community-associated disease outbreaks recovered from cultures in both hospital-onset and community-onset health care-associated infections in all surveillance areas. Invasive MRSA infection affects certain populations disproportionately. It is a major public health problem primarily related to health care but no longer confined to intensive care units, acute care hospitals, or any health care institution.
    No preview · Article · Nov 2007 · JAMA The Journal of the American Medical Association
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Daptomycin, a cyclic lipopeptide antibiotic, was approved by the US Food and Drug Administration (FDA) in September 2003 for the treatment of complicated skin and skin structure infections due to susceptible strains of certain gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA). In May 2006, daptomycin was approved by the FDA for treatment of bacteremia and right-sided endocarditis due to MRSA and methicillin-sensitive S aureus. The aim of this study was to assess the use of daptomycin in community-phenotype (CP)-MRSA infections. Methods: This was a retrospective chart review of data from patients enrolled in a postlabeling registry who received daptomycin for MRSA infections from January to December 2005. CP-MRSA was defined as MRSA susceptible to clindamycin and trimethoprim/sulfamethoxazole; all other phenotypes were considered other-phenotype MRSA (OP-MRSA). Success rates were calculated by dividing success (defined as cure plus improved) by success and failure (including non-evaluable patients). A database search identified 352 patients (100 patients with CP-MRSA [57 men; 43 women]; 252 patients with OP-MRSA [136 men, 116 women]) who met study criteria. Most patients (79.2%) received gram-positive antibiotics before daptomycin. Compared with OP-MRSA, a greater proportion of patients with CP-MRSA were <50 years of age (50.0% vs 35.7%; P = 0.014) and had fewer underlying diseases (mean [SD], 1.7 [1.3] vs 2.5 [1.5]; P < 0.001). Success rate, time to clinical response, and duration of therapy were similar in both groups. Daptomycin was found to be equally effective in treating CP-MRSA and OP-MRSA infections in this selected group of patients.
    Full-text · Article · Dec 2007 · Clinical Therapeutics
Show more